NVCR vs. VIR
NVCR (NovoCure Limited) and VIR (Vir Biotechnology, Inc.) are both stocks. Both are in the Healthcare sector — NVCR in Medical Instruments & Supplies, VIR in Biotechnology. Over the past 5 years, NVCR returned -37.37%/yr vs -24.65%/yr for VIR. Their 0.32 correlation means their historical movements had little consistent relationship.
Performance
NVCR vs. VIR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVCR achieves a 14.77% return, which is significantly lower than VIR's 43.62% return.
NVCR
- 1D
- -2.56%
- 1M
- -13.72%
- 6M
- 19.68%
- YTD
- 14.77%
- 1Y
- 31.10%
- 3Y*
- -23.11%
- 5Y*
- -37.37%
- 10Y*
- 6.60%
- ALL TIME*
- -2.79%
VIR
- 1D
- -2.70%
- 1M
- -13.75%
- 6M
- 16.40%
- YTD
- 43.62%
- 1Y
- 72.17%
- 3Y*
- -15.28%
- 5Y*
- -24.65%
- 10Y*
- —
- ALL TIME*
- -8.75%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
NVCR NovoCure Limited | $41.20M | $32.54M | $29.69M |
| $13.61M | $14.70M | $17.41M |
NVCR vs. VIR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
NVCR NovoCure Limited | 14.77% | -56.61% | 99.60% | -79.65% | -2.30% | -56.61% | 105.34% | 11.63% |
VIR Vir Biotechnology, Inc. | 43.62% | -17.85% | -27.04% | -60.25% | -39.55% | 56.35% | 112.96% | -22.14% |
Correlation
The correlation between NVCR and VIR is 0.43, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.43 |
Correlation (3Y) Balances recent behavior with more history. | 0.43 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.40 |
Correlation (All Time) Calculated using the full available price history since Oct 11, 2019 | 0.32 |
The correlation between NVCR and VIR shifts across timeframes, from 0.32 (all time) to 0.43 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
NVCR:
$1.72B
VIR:
$1.46B
NVCR:
-$1.31
VIR:
-$3.12
NVCR:
2.41
VIR:
18.75
NVCR:
5.09
VIR:
1.57
NVCR:
$699.19M
VIR:
$65.50M
NVCR:
$532.27M
VIR:
$183.11M
NVCR:
-$134.40M
VIR:
-$448.10M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVCR vs. VIR — Risk / Return Rank
NVCR
VIR
NVCR vs. VIR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for NovoCure Limited (NVCR) and Vir Biotechnology, Inc. (VIR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVCR | VIR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.67 | ||
| Sortino ratioReturn per unit of downside risk | -0.69 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.22 | -0.07 |
| Calmar ratioReturn relative to maximum drawdown | 0.87 | 2.78 | -1.91 |
| Martin ratioReturn relative to average drawdown | 1.96 | 6.37 | -4.41 |
Loading charts...
Drawdowns
NVCR vs. VIR - Drawdown Comparison
The maximum NVCR drawdown since its inception was -95.55%, roughly equal to the maximum VIR drawdown of -94.85%. Use the drawdown chart below to compare losses from any high point for NVCR and VIR.
Loading charts...
Drawdown Indicators
| NVCR | VIR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.55% | -94.85% | -0.70% |
Max Drawdown (1Y)Largest decline over 1 year | -32.55% | -25.61% | -6.94% |
Max Drawdown (3Y)Largest decline over 3 years | -69.98% | -69.36% | -0.62% |
Max Drawdown (5Y)Largest decline over 5 years | -93.61% | -92.15% | -1.46% |
Max Drawdown (10Y)Largest decline over 10 years | -95.55% | — | — |
Current DrawdownCurrent decline from peak | -93.42% | -89.58% | -3.84% |
Average DrawdownAverage peak-to-trough decline | -52.73% | -68.14% | +15.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.47% | 11.16% | +3.31% |
Volatility
NVCR vs. VIR - Volatility Comparison
NovoCure Limited (NVCR) has a higher volatility of 32.88% compared to Vir Biotechnology, Inc. (VIR) at 12.38%. This indicates that NVCR's price experiences larger fluctuations and is considered to be riskier than VIR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVCR | VIR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 32.88% | 12.38% | +20.50% |
Volatility (6M)Calculated over the trailing 6-month period | 68.65% | 45.20% | +23.45% |
Volatility (1Y)Calculated over the trailing 1-year period | 79.65% | 69.13% | +10.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 81.23% | 72.66% | +8.57% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 72.18% | 95.40% | -23.22% |
Dividends
NVCR vs. VIR - Dividend Comparison
Neither NVCR nor VIR has paid dividends to shareholders.
Financials
NVCR vs. VIR - Financials Comparison
This section allows you to compare key financial metrics between NovoCure Limited and Vir Biotechnology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NVCR and VIR have a correlation of 0.43, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NVCR has higher volatility (32.88%) compared to VIR (12.38%). In terms of maximum drawdown, NVCR dropped -95.55% vs VIR's -94.85%.
VIR currently has the higher Sharpe Ratio (1.03 vs 0.36), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVCR and VIR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer